MENU
Alnylam Supports Bleeding Disorders Month and World Hemophilia Day

Alnylam Supports Bleeding Disorders Month and World Hemophilia Day

“Bleeding Disorders Awareness Month,” was recently approved by the U.S. Department of Health and Human Services (HHS) as a National Health Observance in March. In previous years, March was dedicated to Hemophilia Awareness but through this new initiative, it has been expanded to unite the community and raise awareness of all inherited bleeding disorders and their potential health problems.

Behind the Mystery: Rare + Genetic Series - TTR Amyloid

Behind the Mystery: Rare & Genetic Series - TTR Amyloid

Battling a rare medical condition, that's often misdiagnosed.
Imagine having a rare, debilitating disease that's passed down through families. Dr. John Berk, Associate Professor of Medicine at Boston University and Clinical Director of its Amyloidosis Center, joins us to discuss the medical condition called Transthyretin-Mediated Amyloidosis. It's symptoms are similar to other conditions and ATTR patients are very often misdiagnosed. We discuss symptoms, family connections and treatment options, in this Behind the Mystery: Rare & Genetic segment. And meet Dylan Duncan, who's battling the disease. You don't want to miss this.

Complete 18-Month Data from Ongoing Phase 2 OLE Study with Patisiran in Development for the Treatment of Hereditary TTR-Mediated Amyloidosis with Polyneuropathy (hATTR-PN)

We reported results from our ongoing Phase 2 open-label extension (OLE) study with patisiran at the 68th Annual Meeting of the American Academy of Neurology (AAN), held April 15 – 21, 2016 in Vancouver, British Columbia, Canada.  Complete 18-month data (N=27) from the study provided continued evidence that patisiran has the potential to halt neuropathy progression in patients with hATTR-PN (also known as familial amyloidotic polyneuropathy, or FAP), showing a mean 0.8-point decrease in mNIS+7, which compares favorably to an estimated increase in mNIS+7 of 22 to 26 points at 18 months based upon analysis of historical data sets in untreated hATTR-PN patients with similar baseline neurologic impairment. Patisiran administration was also associated with a statistically significant, approximately 77% median improvement in nerve fiber density as read histologically in a blinded manner from distal thigh sweat gland biopsy samples.

Further, in the first reported exploratory analysis of its kind, the degree of TTR knockdown observed in patients was shown to correlate with improvement in mNIS+7 scores, supporting the therapeutic hypothesis that reduction of mutant and wild-type TTR may be associated with potential halting of neuropathy progression in patients with hATTR-PN.

Importantly, patisiran was found to be generally well tolerated out to 25 months of treatment.  There were no drug-related severe adverse events (SAEs), and the majority of reported adverse events (AEs) were mild to moderate.  The most common drug-related or possibly drug-related AEs were flushing (22.2%) and infusion-related reactions, or “IRRs” (18.5%). All IRRs and drug-related flushing AEs were mild in severity and did not result in any discontinuations.  In addition, there were no clinically significant changes in liver function tests, renal function tests, or other laboratory or hematologic parameters, including platelets.



Read More

New Program Added to Genetic Medicines Pipeline: ALN-F12

New Program Added to Genetic Medicines Pipeline: ALN-F12

We’re announcing the addition of a new program to our genetic medicines pipeline, ALN-F12, an investigational RNAi therapeutic targeting F12 for the treatment of Hereditary Angioedema (HAE). Pre-clinical data for ALN-F12 were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual meeting, held March 4-7, 2016.

HAE is a genetic disorder characterized by episodes of severe swelling in various parts of the body, including the face, hands, feet, gastrointestinal tract, and airways. It is caused by a defect in the C1-inhibitor gene that results in poor control of contact pathway activation and excessive bradykinin generation. Elevated levels of bradykinin increase vascular permeability, ultimately causing the episodic swelling attacks that are characteristic of HAE. The F12 gene encodes Factor XII (FXII), which is at the top of the contact pathway cascade. Pre-clinical data showed that administration of ALN-F12 resulted in dose-dependent reduction of vascular permeability in two different mouse models of bradykinin-driven vascular leakage, demonstrating that suppression of F12 mRNA has the potential to mitigate excess bradykinin stimulation. Further, in non-human primates, a single subcutaneous dose of ALN-F12 at 3 mg/kg resulted in potent and durable knockdown of serum FXII of greater than 85 percent, with knockdown of over 50 percent sustained out to three months following administration.


Read More

Positive Data with Monthly Dosing Cohorts from Ongoing Phase 1 Trial with Fitusiran (ALN-AT3) for the Treatment of Hemophilia and Rare Bleeding Disorders

Positive Data with Monthly Dosing Cohorts from Ongoing Phase 1 Trial with Fitusiran (ALN-AT3) for the Treatment of Hemophilia and Rare Bleeding Disorders

We reported new data from our Phase 1 study with the newly named fitusiran (ALN-AT3), an investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders. Interim results – presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held December 5 – 8, 2015 – showed that monthly, subcutaneous administration of fitusiran achieved potent and dose-dependent lowering of AT of up to 88% in patients with hemophilia. This AT lowering was associated with statistically significant increases in thrombin generation and an 85% reduction in estimated median annualized bleeding rates (ABR) in all evaluable cohorts. The observed bleeding rates are comparable to those reported for prophylactic intravenous infusions of replacement factors in patients with hemophilia. Fitusiran was found to be generally well tolerated to date, including no thromboembolic events or clinically significant increases in D-dimer, a biomarker of excessive clot formation.



Read More

Positive Interim Results from Phase 1/2 Clinical Study with ALN-CC5 for the Treatment of Complement-Mediated Diseases

Positive Interim Results from Phase 1/2 Clinical Study with ALN-CC5 for the Treatment of Complement-Mediated Diseases

We reported new data from our ongoing Phase 1/2 clinical study with ALN-CC5, an investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases. Data were presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held December 5 – 8, 2015.  Results showed that administration of ALN-CC5 achieved up to 99% knockdown of serum C5 and up to 98% inhibition of serum hemolytic activity, an assay for complement activity.  Further, ALN-CC5 administration resulted in low levels of residual C5, which – based on comparisons from separate studies – were at or below the estimated levels of free C5 observed at therapeutic doses of eculizumab, an approved anti-C5 monoclonal antibody. The effects were also found to be highly durable, with C5 knockdown and complement inhibition results supporting a once monthly and possibly a once quarterly subcutaneous dose regimen.  Importantly, ALN-CC5 was shown to be generally well tolerated, with no clinically significant, drug-related adverse events to date.




Read More